This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Talbott, E. O. Articles by Guzick, D. S. Search for Related Content PubMed PubMed Citation Articles by Talbott, E. O. Articles by Guzick, D. S.

Evidence for an Association between Metabolic Cardiovascular Syndrome and Coronary and Aortic Calcification among Women with Polycystic Ovary Syndrome

Department of Epidemiology, University of Pittsburgh, Graduate School of Public Health (E.O.T., J.V.Z., J.R.R., M.Y.B.), Pittsburgh, Pennsylvania 15261; Preventive Heart Care Center, University of Pittsburgh Medical Center (D.A.E.), Pittsburgh, Pennsylvania 15213; and University of Rochester School of Medicine (D.S.G.), Rochester, New York 14642

Address all correspondence and requests for reprints to: Dr. Evelyn O. Talbott, Department of Epidemiology, University of Pittsburgh, 130 DeSoto Street, A526 Crabtree Hall/GSPH, Pittsburgh, Pennsylvania 15261. E-mail: eot1{at}pitt.edu.

Women with polycystic ovary syndrome (PCOS) exhibit an adverse cardiovascular risk profile, characteristic of the metabolic cardiovascular syndrome (MCS). The aim of this study was to determine the prevalence of coronary artery (CAC) and aortic (AC) calcification among middle-aged PCOS cases and controls and to explore the relationship among calcification, MCS, and other cardiovascular risk factors assessed 9 yr earlier. This was a prospective study of 61 PCOS cases and 85 similarly aged controls screened in 1993–1994 for risk factors and reevaluated in 2001–2002. The main outcome measures were CAC and AC, measured by electron beam tomography. Women with PCOS had a higher prevalence of CAC (45.9% vs. 30.6%) and AC (68.9% vs. 55.3%) than controls. After adjustment for age and body mass index, PCOS was a significant predictor of CAC (odds ratio = 2.31; P = 0.049). PCOS subjects were also 4.4 times more likely to meet the criteria for MCS than controls. High-density lipoprotein cholesterol and insulin appeared to mediate the PCOS influence on CAC. Interestingly, total testosterone was an independent risk factor for AC in all subjects after controlling for PCOS, age, and body mass index (P = 0.034). We conclude that women with PCOS are at increased risk of MCS and demonstrate increased CAC and AC compared with controls. Components of MCS mediate the association between PCOS and CAC, independently of obesity.

This article has been cited by other articles:

				M. Luque-Ramirez, C. Mendieta-Azcona, J. M del Rey Sanchez, M. Maties, and H. F Escobar-Morreale Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking Eur. J. Endocrinol., March 1, 2009; 160(3): 469 - 480. [Abstract] [Full Text] [PDF]

				W. Kosmala, T. M. O'Moore-Sullivan, R. Plaksej, J. Kuliczkowska-Plaksej, M. Przewlocka-Kosmala, and T. H. Marwick Subclinical Impairment of Left Ventricular Function in Young Obese Women: Contributions of Polycystic Ovary Disease and Insulin Resistance J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3748 - 3754. [Abstract] [Full Text] [PDF]

				A. J. Cussons, G. F. Watts, V. Burke, J. E. Shaw, P. Z. Zimmet, and B. G.A. Stuckey Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome Hum. Reprod., October 1, 2008; 23(10): 2352 - 2358. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, S. Livadas, S. A Kandarakis, A. Margeli, and I. Papassotiriou Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur. J. Endocrinol., April 1, 2008; 158(4): 525 - 531. [Abstract] [Full Text] [PDF]

				D. S. Guzick Do Cardiovascular Risk Factors in Polycystic Ovarian Syndrome Result in More Cardiovascular Events? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1170 - 1171. [Full Text] [PDF]

				J. E. Nestler Metformin for the Treatment of the Polycystic Ovary Syndrome N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54. [Full Text] [PDF]

				R. Shroff, A. Kerchner, M. Maifeld, E. J. R. Van Beek, D. Jagasia, and A. Dokras Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4609 - 4614. [Abstract] [Full Text] [PDF]

				M. Luque-Ramirez, C. Mendieta-Azcona, F. Alvarez-Blasco, and H. F. Escobar-Morreale Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome Hum. Reprod., December 1, 2007; 22(12): 3197 - 3203. [Abstract] [Full Text] [PDF]

				L. J. Moran, M. Noakes, P. M. Clifton, G. A. Wittert, D. P. Belobrajdic, and R. J. Norman C-Reactive Protein before and after Weight Loss in Overweight Women with and without Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2944 - 2951. [Abstract] [Full Text] [PDF]

				T. Sir-Petermann, B. Echiburu, M M. Maliqueo, N. Crisosto, F. Sanchez, C. Hitschfeld, M. Carcamo, P. Amigo, and F. Perez-Bravo Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome Hum. Reprod., July 1, 2007; 22(7): 1830 - 1836. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions. Diabetes Care, September 1, 2006; 29(9): 2165 - 2174. [Full Text] [PDF]

				T. L. Setji, N. D. Holland, L. L. Sanders, K. C. Pereira, A. M. Diehl, and A. J. Brown Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1741 - 1747. [Abstract] [Full Text] [PDF]

				J. C. Lo, S. L. Feigenbaum, J. Yang, A. R. Pressman, J. V. Selby, and A. S. Go Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1357 - 1363. [Abstract] [Full Text] [PDF]

				E Carmina, N Napoli, R A Longo, G B Rini, and R A Lobo Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS Eur. J. Endocrinol., January 1, 2006; 154(1): 141 - 145. [Abstract] [Full Text] [PDF]

				H. F. Escobar-Morreale, J. I. Botella-Carretero, F. Alvarez-Blasco, J. Sancho, and J. L. San Millan The Polycystic Ovary Syndrome Associated with Morbid Obesity May Resolve after Weight Loss Induced by Bariatric Surgery J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6364 - 6369. [Abstract] [Full Text] [PDF]

				R. Azziz, C. Marin, L. Hoq, E. Badamgarav, and P. Song Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4650 - 4658. [Abstract] [Full Text] [PDF]

				E. B. Kilicdag, T. Bagis, E. Tarim, E. Aslan, S. Erkanli, E. Simsek, B. Haydardedeoglu, and E. Kuscu Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial Hum. Reprod., June 1, 2005; 20(6): 1521 - 1528. [Abstract] [Full Text] [PDF]